Danish company Novo Nordisk AS in buyout agreement with Biopart
Through its current controlling shareholder company Biopart Ltda, Novo Nordisk AS is to acquire control of the Brazilian pharmaceutical company Biobrás, which specialises in insulin production. Denmark’s Novo Nordisk is acting through its subsidiary NN Holding do Brasil Ltda. The agreement was executed on December 12.
To read more
Subscribe to Latin Lawyer
Subscribe and start reading now
Latin Lawyer is your definitive source of news, analysis, and research from the Latin American legal community. It keeps you up to speed with the issues and trends that matter and provides the data and tools you need to operate successfully.